Beyond the Lump: Understanding Rare Breast Cancer Types

Breast cancer is often imagined as a single, uniform disease — a lump detected, followed by surgery and chemotherapy. In reality, breast cancer is not one condition but a spectrum of diseases arising in the breast, each with distinct biological behaviour and treatment pathways. While the most common form — invasive carcinoma of no special type (NST), formerly called invasive ductal carcinoma — accounts for nearly 70–80% of cases, several less common subtypes significantly influence diagnosis, prognosis and management. In India, where breast cancer is now the most frequently diagnosed cancer among women in many urban registries, understanding these variations is critical for early detection and effective care.

From Imaging to Pathology: Why Subtype Matters

Once a breast abnormality is detected through clinical examination or imaging, the definitive step is tissue diagnosis, usually via core needle biopsy. Under the microscope, pathologists examine cell patterns and test for hormone receptors — oestrogen (ER), progesterone (PR) — and HER2 status.

The pathology report determines:

• Whether cancer is present.
• The tissue of origin — ducts or lobules.
• The cellular growth pattern.
• Hormone receptor and HER2 expression.

Two individuals may both be diagnosed with “breast cancer,” yet have biologically different diseases requiring distinct treatments. This is why coordination between radiologists, pathologists and surgeons — ideally within multidisciplinary breast units — is essential, especially when dealing with rare subtypes.

Invasive Lobular Carcinoma: The Subtle Second Commonest

The most important non-ductal subtype is invasive lobular carcinoma (ILC), which accounts for roughly 10% of invasive breast cancers. Unlike typical ductal cancers that form compact lumps, ILC begins in the milk-producing lobules and spreads in single-file patterns under the microscope.

This growth pattern results in unique clinical features:

• May not form a well-defined lump.
• Can cause generalized thickening or fullness of one breast.
• Often produces subtle nipple or skin changes.
• Can be difficult to detect on mammography.

Most ILC cases are hormone receptor–positive and respond well to long-term anti-oestrogen therapy. When detected early, outcomes are generally favourable. The key challenge lies in recognising that breast awareness is not limited to feeling a discrete lump but noticing persistent changes in shape, firmness or symmetry.

Biologically Gentle Subtypes with Good Outcomes

Not all rare breast cancers behave aggressively. Certain subtypes tend to grow slowly and have excellent prognoses when treated appropriately:

• Tubular carcinoma — composed of well-formed tube-like structures; typically small and slow-growing.
• Mucinous (colloid) carcinoma — cancer cells appear to float in pools of mucus; often seen in older women and less aggressive.
• Adenoid cystic carcinoma — rare, low-grade tumour with a distinctive cribriform pattern and low lymph node involvement.

In many such cases, treatment may involve surgery followed by hormone therapy, without the need for intensive chemotherapy. Early diagnosis remains the most decisive factor.

Aggressive Variants: When Microscopy Signals Caution

Certain rare subtypes require heightened vigilance due to their tendency for rapid spread or treatment resistance.

• Invasive micropapillary carcinoma — characterised by clusters of cells appearing to float in spaces; associated with higher lymphovascular invasion and lymph node involvement.
• Metaplastic carcinoma — contains areas resembling bone, cartilage or connective tissue; often triple-negative (lacking ER, PR, HER2) and less responsive to conventional chemotherapy.

These variants underline the importance of precise pathological diagnosis and tailored systemic therapy. Outcomes depend heavily on early staging and access to specialised care.

Phyllodes Tumours: Not Carcinoma, Yet Clinically Important

Phyllodes tumours differ from typical breast carcinomas. They arise from both fibrous and glandular tissue and are classified as benign, borderline or malignant based on microscopic features.

Clinically, they:

• Present as smooth, mobile lumps.
• May initially resemble fibroadenomas.
• Can grow rapidly over months.

Unlike typical breast cancers, lymph node spread is uncommon. Treatment primarily involves wide surgical excision to prevent recurrence. Malignant forms may spread through the bloodstream, most often to the lungs. Rapid enlargement of a previously “benign” lump warrants re-evaluation.

Male Breast Cancer: The Overlooked Reality

Breast cancer is often perceived as a women’s disease, but men also possess breast tissue and can develop malignancies. Warning signs include:

• A firm lump near or behind the nipple.
• Nipple retraction or ulceration.
• Discharge, including blood-stained fluid.
• Enlarged lymph nodes in the armpit.

Treatment principles mirror those in women — surgery, hormone therapy for receptor-positive disease, and chemotherapy or targeted therapy when indicated. Early detection significantly improves outcomes. Social stigma and lack of awareness often delay diagnosis in men.

Red Flags That Should Never Be Ignored

While the specific subtype cannot be determined without pathology, certain symptoms warrant prompt evaluation:

• A new lump in the breast or armpit persisting beyond a few weeks.
• Rapid growth of a known “benign” lump.
• Noticeable asymmetry in size, shape or firmness.
• Nipple inversion, distortion or blood-stained discharge.
• Persistent skin thickening or dimpling.

Most breast changes are benign, but timely imaging and biopsy provide clarity and prevent dangerous delays.

What to Note for Prelims?

• Difference between invasive carcinoma NST and invasive lobular carcinoma.
• Meaning of hormone receptor status (ER, PR) and HER2.
• Concept of triple-negative breast cancer.
• Role of core needle biopsy in diagnosis.
• Classification of phyllodes tumours.

What to Note for Mains?

• Importance of early detection in reducing breast cancer mortality.
• Role of multidisciplinary care in oncology management.
• Challenges of cancer awareness and stigma in India.
• Public health implications of rising breast cancer incidence.
• Need for strengthening pathology and cancer registry systems.

Breast cancer is not a single narrative but a diverse group of diseases, each requiring accurate diagnosis and thoughtful management. Early recognition, multidisciplinary care, and public awareness remain the most powerful tools in improving outcomes across this varied spectrum.